Form 4: FibroBiologics Executive Receives Stock Grant
Insider Transaction (Form 4)
Hamid Khoja, Chief Scientific Officer of FibroBiologics, Inc., reported multiple transactions in common stock on September 15, 2026.
Summary
- Grant/award: acquired 298,508 Common Stock at $1.68 ($500,001) on September 15, 2026; holds 301,571 after (Direct).
- Grant/award: acquired 298,508 Warrant (Right to Buy) on September 15, 2026; holds 298,508 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Hamid Khoja — Officer (Chief Scientific Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-15 | Grant/award | Common Stock | 298,508 | $2 | $500.0K | 301,571 |
| 2026-09-15 | Grant/award | Warrant (Right to Buy) | 298,508 | — | — | 298,508 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-15 | Grant/award (298,508 shares) |
| 2026-09-15 | Grant/award (298,508 shares) |
Keywords
insider transaction, Form 4, FBLG, FibroBiologics, Inc., neutral, Hamid Khoja
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.